<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18711282</article-id>
      <article-id pub-id-type="pmc">2636151</article-id>
      <article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_5_438_42430</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Combined photodynamic therapy
and intravitreal ranibizumab as
primary treatment for choroidal
neovascularization associated with
age-related macular degeneration in
an Indian patient</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Rishi</surname>
            <given-names>Pukhraj</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sen</surname>
            <given-names>Pratik Ranjan</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shroff</surname>
            <given-names>Daraius</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chhablani</surname>
            <given-names>Jay</given-names>
          </name>
          <degrees>MS</degrees>
        </contrib>
      </contrib-group>
      <aff>Shri Bhagwan Mahavir Vitreretinal Services, Sankara Nethralaya,
18, College Road, Chennai - 600 006, Tamil Nadu, India</aff>
      <author-notes>
        <corresp id="cor1">Correspondence to Dr. Pukhraj Rishi, Sankara Nethralaya,
18, College Road, Chennai - 600 006, Tamil Nadu, India.
Email: <email>docrishi@yahoo.co.in</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2008</year>
      </pub-date>
      <volume>56</volume>
      <issue>5</issue>
      <fpage>438</fpage>
      <lpage>439</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0
Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>We report the efficacy of combination therapy using
photodynamic therapy (PDT) and intravitreal ranibizumab
for choroidal neovascular membrane (CNVM) associated with
age-related macular degeneration (ARMD) in an Indian patient,
for the first time.</p>
    <p>A 65-year-old lady presented with decreased vision in
the left eye since four weeks. Right eye was phthisical with
no perception of light. Vision was 20/80 in the left eye.
Biomicroscopic evaluation of the anterior segment was
unremarkable except for early cataractous changes. Fundus
examination revealed an extrafoveal CNVM underlying the
papillomacular bundle [Figure <xref ref-type="fig" rid="F1A">1A</xref>]. Clinical findings were
corroborated on fundus fluorescein angiography (FFA) [Figure
<xref ref-type="fig" rid="F1B">1B</xref>] and optical coherence tomography (OCT) [Figure <xref ref-type="fig" rid="F1C">1C</xref>].
Considering the location of the CNVM and the single-eyed
status of the patient, laser photocoagulation was thought to
be best avoided. The patient underwent PDT as per standard
protocol followed by intravitreal ranibizumab (0.5 mg), two
days later. No treatment-related adverse effect was noted. At
16 weeks follow-up, visual acuity improved to 20/20. Clinical
examination revealed regression of CNVM with no evidence
of subretinal fluid. Clinical findings were confirmed on OCT
which revealed a scarred CNVM with restoration of the retinal
thickness and foveal contour <xref ref-type="fig" rid="F2">Figure 2</xref>. The fundus remained
stable and visual acuity was maintained at the sixth month
follow-up.</p>
    <p>Ranibizumab (Lucentis, Genetech, Inc, South San Francisco,
California, USA) is an FDA-approved monoclonal antibody
fragment that targets all vascular endothelial growth factor
(VEGF)-A isoforms.<xref ref-type="bibr" rid="ref1">1</xref> Combined treatment using PDT and
bevacizumab has been shown to be effective in improving
visual acuity and decreasing retreatment rates in choroidal
neovascularization (CNV) associated with ARMD.<xref ref-type="bibr" rid="ref2">2</xref> The
combined regime is postulated to have a beneficial synergistic
effect that could reduce the need for cyclic injections.<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></p>
    <p>Combination therapy using ranibizumab and PDT has
been reported previously in a single clinical trial in the
Western literature, where the combination was found to be
more efficacious than PDT alone.<xref ref-type="bibr" rid="ref4">4</xref> VEGF inhibition alone
could prevent neovascularization at an early developmental
stage. However, once neovascular beds are established they
are unlikely to regress with anti-VEGF therapy alone.<xref ref-type="bibr" rid="ref3">3</xref> At this
stage, a combined approach using a non-thermal laser has been
seen to be beneficial. Since it is still unknown as to which stage
CNV would become unresponsive to VEGF inhibition alone,
combination therapy treatment using PDT and ranibizumab
as the first-line management in such cases could be a viable
option.</p>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenfeld</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lalwani</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Ranibizumab: Phase III clinical trial results</article-title>
          <source>Ophthalmol Clin North Am</source>
          <year>2006</year>
          <volume>19</volume>
          <fpage>361</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">16935211</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spaide</surname>
              <given-names>RF</given-names>
            </name>
          </person-group>
          <article-title>Rationale for combination therapies for choroidal
neovascularization</article-title>
          <source>Am J Ophthalmol</source>
          <year>2006</year>
          <volume>141</volume>
          <fpage>149</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">16386991</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhalla</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Blinder</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>EH</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Mittra</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Tewari</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Combined photodynamic therapy with verteporfin and intravitreal
bevacizumab for choroidal neovascularization in age-related
macular degeneration</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>988</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">17151484</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heier</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Boyer</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Ciulla</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Ferrone</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Jumper</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Gentile</surname>
              <given-names>RC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ranibizumab combined with verteporfin photodynamic
therapy in neovascular age-related macular degeneration: Year 1
results of the FOCUS Study</article-title>
          <source>Arch Ophthalmol</source>
          <year>2006</year>
          <volume>124</volume>
          <fpage>1532</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">17101999</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1A" position="float">
      <label>Figure 1A</label>
      <caption>
        <p>(A) Color fundus photograph of the left eye reveals a choroidal
neovascular membrane underlying the papillomacular bundle. Hard
exudates and subretinal hemorrhages are noted surrounding it.</p>
      </caption>
      <alt-text>Figure 1A</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-438-g001"/>
    </fig>
    <fig id="F1B" position="float">
      <label>Figure 1B</label>
      <caption>
        <p>(B) Fundus fluorescein angiography reveals the presence of leakage from
the lesion characteristic of a classic choroidal neovascular membrane.</p>
      </caption>
      <alt-text>Figure 1B</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-438-g002"/>
    </fig>
    <fig id="F1C" position="float">
      <label>Figure 1C</label>
      <caption>
        <p>(C) Optical coherence tomography reveals the presence of a choroidal
neovascular membrane with subfoveal fluid</p>
      </caption>
      <alt-text>Figure 1C</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-438-g003"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Optical coherence tomography reveals the presence of a
scarred choroidal neovascular membrane with restoration of retinal
thickness and foveal contour</p>
      </caption>
      <alt-text>Figure 2</alt-text>
      <graphic xlink:href="IndianJOphthalmol-56-438-g004"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
